$2.39
9.81% yesterday
NYSE, Nov 15, 10:00 pm CET
ISIN
CH0499880968
Symbol
ADCT
Sector
Industry

Adc Therapeutics SA Target price 2024 - Analyst rating & recommendation

Adc Therapeutics SA Classifications & Recommendation:

Buy
83%
Hold
17%

Adc Therapeutics SA Price Target

Target Price $8.50
Price $2.39
Potential
Number of Estimates 4
4 Analysts have issued a price target Adc Therapeutics SA 2025 . The average Adc Therapeutics SA target price is $8.50. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 5 Analysts recommend Adc Therapeutics SA to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Adc Therapeutics SA stock has an average upside potential 2025 of . Most analysts recommend the Adc Therapeutics SA stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 69.56 72.57
66.86% 4.32%
EBITDA Margin -231.61% -190.17%
302.73% 17.89%
Net Margin -408.67% -226.96%
345.83% 44.46%

6 Analysts have issued a sales forecast Adc Therapeutics SA 2024 . The average Adc Therapeutics SA sales estimate is

$72.6m
Unlock
. This is
2.61% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$73.8m 4.36%
Unlock
, the lowest is
$71.9m 1.67%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $69.6m 66.86%
2024
$72.6m 4.32%
Unlock
2025
$81.1m 11.69%
Unlock
2026
$112m 38.80%
Unlock
2027
$171m 51.91%
Unlock
2028
$264m 54.22%
Unlock

1 Analyst has issued an EBITDA forecast Adc Therapeutics SA 2024 . The average Adc Therapeutics SA EBITDA estimate is

$-138m
Unlock
. This is
3.70% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-138m 3.70%
Unlock
, the lowest is
$-138m 3.70%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-161m 33.46%
2024
$-138m 14.34%
Unlock
2025
$-166m 20.29%
Unlock
2026
$-159m 4.22%
Unlock

EBITDA Margin

2023 -231.61% 302.73%
2024
-190.17% 17.89%
Unlock
2025
-204.81% 7.70%
Unlock
2026
-141.33% 30.99%
Unlock

6 Adc Therapeutics SA Analysts have issued a net profit forecast 2024. The average Adc Therapeutics SA net profit estimate is

$-165m
Unlock
. This is
29.03% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-136m 41.25%
Unlock
, the lowest is
$-181m 22.08%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-284m 47.74%
2024
$-165m 42.06%
Unlock
2025
$-145m 12.04%
Unlock
2026
$-112m 22.97%
Unlock
2027
$-84.4m 24.40%
Unlock
2028
$-31.7m 62.46%
Unlock

Net Margin

2023 -408.67% 345.83%
2024
-226.96% 44.46%
Unlock
2025
-178.75% 21.24%
Unlock
2026
-99.19% 44.51%
Unlock
2027
-49.36% 50.24%
Unlock
2028
-12.01% 75.67%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -2.94 -1.70
47.74% 42.18%
P/E negative
EV/Sales 1.12

6 Analysts have issued a Adc Therapeutics SA forecast for earnings per share. The average Adc Therapeutics SA <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.70
Unlock
. This is
29.17% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.41 41.25%
Unlock
, the lowest is
$-1.87 22.08%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-2.94 47.74%
2024
$-1.70 42.18%
Unlock
2025
$-1.50 11.76%
Unlock
2026
$-1.15 23.33%
Unlock
2027
$-0.87 24.35%
Unlock
2028
$-0.33 62.07%
Unlock

P/E ratio

Current -1.00 376.19%
2024
-1.40 40.00%
Unlock
2025
-1.60 14.29%
Unlock
2026
-2.07 29.38%
Unlock
2027
-2.74 32.37%
Unlock
2028
-7.30 166.42%
Unlock

Based on analysts' sales estimates for 2024, the Adc Therapeutics SA stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.15 194.26%
2024
1.12 2.50%
Unlock
2025
1.00 10.47%
Unlock
2026
0.72 27.95%
Unlock
2027
0.48 34.18%
Unlock
2028
0.31 35.16%
Unlock

P/S ratio

Current 3.27 956.82%
2024
3.18 2.55%
Unlock
2025
2.85 10.47%
Unlock
2026
2.05 27.96%
Unlock
2027
1.35 34.17%
Unlock
2028
0.88 35.16%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today